Aurobindo Pharma is currently trading at Rs. 395.10, up by 10.15 points or 2.64% from its previous closing of Rs. 384.95 on the BSE.
The scrip opened at Rs. 382.00 and has touched a high and low of Rs. 399.00 and Rs. 380.00 respectively. So far 84,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 417.90 on 07-Jan-2014 and a 52 week low of Rs. 127.15 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs. 402.70 and Rs. 375.00 respectively. The current market cap of the company is Rs. 11,574.00 crore.
The promoters holding in the company stood at 54.73% while Institutions and Non-Institutions held 31.56% and 13.71% respectively.
Aurobindo Pharma has inked a binding offer to acquire commercial operations in seven Western European countries from Actavis plc. The closing of the transaction is conditional on certain antitrust approvals and completion of employee consultation processes. The company expects to acquire personnel, commercial infrastructure, products, marketing authorizations and dossier license rights in seven European countries.
Actavis and Aurobindo will be entering into a long term commercial and supply arrangement in order to support the ongoing growth plans of these businesses. The acquisition expands Aurobindo’s front-end operations into five segments (generics, prescription products, over-the-counter products, hospital products and generics tenders) with approximately 1200 products and an additional pipeline of over 200 products. The management estimates the net sales for the acquired businesses would be around EUR 320 million in 2013 with a growth rate of over 10% year-on-year.
Although these businesses are currently loss-making, Aurobindo Pharma expects them to return to profitability in combination with its vertically integrated platform and existing commercial infrastructure. The acquisition will make Aurobindo one of the leading Indian pharmaceutical companies in Europe. This acquisition will also enable Aurobindo to achieve critical mass in Western Europe with a top 10 position in several key markets.
Jefferies International acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo Pharma. Rothschild and Latham & Watkins acted as sole financial adviser and legal counsel to Actavis, respectively.
The scrip opened at Rs. 382.00 and has touched a high and low of Rs. 399.00 and Rs. 380.00 respectively. So far 84,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 417.90 on 07-Jan-2014 and a 52 week low of Rs. 127.15 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs. 402.70 and Rs. 375.00 respectively. The current market cap of the company is Rs. 11,574.00 crore.
The promoters holding in the company stood at 54.73% while Institutions and Non-Institutions held 31.56% and 13.71% respectively.
Aurobindo Pharma has inked a binding offer to acquire commercial operations in seven Western European countries from Actavis plc. The closing of the transaction is conditional on certain antitrust approvals and completion of employee consultation processes. The company expects to acquire personnel, commercial infrastructure, products, marketing authorizations and dossier license rights in seven European countries.
Actavis and Aurobindo will be entering into a long term commercial and supply arrangement in order to support the ongoing growth plans of these businesses. The acquisition expands Aurobindo’s front-end operations into five segments (generics, prescription products, over-the-counter products, hospital products and generics tenders) with approximately 1200 products and an additional pipeline of over 200 products. The management estimates the net sales for the acquired businesses would be around EUR 320 million in 2013 with a growth rate of over 10% year-on-year.
Although these businesses are currently loss-making, Aurobindo Pharma expects them to return to profitability in combination with its vertically integrated platform and existing commercial infrastructure. The acquisition will make Aurobindo one of the leading Indian pharmaceutical companies in Europe. This acquisition will also enable Aurobindo to achieve critical mass in Western Europe with a top 10 position in several key markets.
Jefferies International acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo Pharma. Rothschild and Latham & Watkins acted as sole financial adviser and legal counsel to Actavis, respectively.
No comments:
Post a Comment